Close Menu

NEW YORK – Oncocyte said Tuesday that it has agreed to acquire German diagnostics firm Chronix Biomedical.

Under the agreement, which supersedes a previously announced collaboration between the companies, Oncocyte will acquire Chronix's cancer immunotherapy monitoring test, TheraSure-CNI Monitor, as well as the intellectual property for its organ transplant monitoring technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.